Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 6/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.48 |
| ▸ | NPY1R | P25929 | 4/20 | 0.48 |
| ▸ | NMT1 | P30419 | 4/20 | 0.47 |
| ▸ | NMT2 | O60551 | 3/20 | 0.47 |
| ▸ | NPY2R | P49146 | 2/20 | 0.42 |
| ▸ | TLR2 | O60603 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | FURIN | P09958 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18862076 | 0.95 | NMT1 (0.55) | NPY4RNPY5RNPY1RNMT1NMT2 | |
| SCHEMBL16359306 | 0.87 | NMT1 (0.54) | NPY4RNPY5RNPY1RNMT1NMT2 | |
| SCHEMBL16359357 | 0.87 | NMT1 (0.54) | NPY4RNPY5RNPY1RNMT1NMT2 | |
| SCHEMBL29458673 | 0.84 | TLR2 (0.59) | NPY4RNPY5RNPY1RNMT1NMT2 | |
| SCHEMBL30286903 | 0.84 | TLR2 (0.59) | NPY4RNPY5RNPY1RNMT1NMT2 | |
| SCHEMBL28354912 | 0.84 | TLR2 (0.59) | NPY4RNPY5RNPY1RNMT1NMT2 | |
| SCHEMBL15185934 | 0.83 | FAAH (0.47) | NMT1NMT2TLR2SLC6A5 | |
| SCHEMBL10592847 | 0.82 | NMT1 (0.50) | NPY4RNPY5RNPY1RNMT1NMT2 | |
| SCHEMBL13356185 | 0.82 | FAAH (0.44) | NMT1NMT2SLC6A5 | |
| SCHEMBL30979546 | 0.81 | TLR2 (0.58) | NMT1NMT2TLR2SLC6A5FURIN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | NPY4R 3333/4885NPY5R 3227/4885NPY1R 2447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.